Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move
Quince Therapeutics shares dropped 6.6% to $0.13 in premarket trading after the company hired LifeSci Capital to advise on strategic alternatives and liability restructuring. The move follows a failed Phase 3 trial in late January and the resignation of five directors. Quince said it will not provide further updates unless its board approves a specific action.
